Finally, Harvey et al. assessed the impact of osimertinib on the PK of simvastatin, a sensitive CYP3A substrate, and rosuvastatin, a breast cancer resistance protein (BCRP) substrate, in patients with EGFR mutation-positive NSCLC following progression on an EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.